In accordance with their mechanism of action, all marketed GLP-1 RAs are indicated to improve glycaemic control in people with type 2 diabetes (Müller et al., 2019; Nauck et al., 2020). This evidence concerns the gene GCG and type 2 diabetes mellitus.